🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rosa Nadal

University of Washington

ORCID: 0000-0002-6836-9731

Also affiliated with Fred Hutch Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Papers

Driven by 12 papers — median percentile 0. Top paper: “Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors”.

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652
N/A
3.5DataRank · unranked
138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30202-3
N/A
3.0DataRank · unranked
89 citations

Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg +27 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726
N/A
1.1DataRank · unranked
24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009147
N/A
0.763DataRank · unranked
13 citations

Elizabeth M. Brahmbhatt, Elena Cherkasova, Timothy T. Spear, Ujjawal Savani, Stephanie Pierre +13 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1
N/A
0DataRank · unranked
0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16506
N/A
0DataRank · unranked
0 citations

Elias Chandran, Nicholas I. Simon, Lisa Ley, Lisa M. Cordes, Tzu-fang Wang +13 more

Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR

Molecular Therapy — Methods & Clinical Development(2024)10.1016/j.omtm.2024.101324
N/A
0DataRank · unranked
0 citations

Elena Cherkasova, Rosa Nadal, Xin Tian, Long Chen, Angelina Parrizzi +5 more

Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2549
N/A
0DataRank · unranked
5 citations

Stefan Barisic, Gina Scurti, Elena Cherkasova, Long Chen, Kristen Wood +13 more

T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4542
N/A
0DataRank · unranked
2 citations

Elizabeth M. Brahmbhatt, Elena Cherkasova, Rosa Nadal, Ujjawal Savani, Stephanie Pierre +12 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more